Evidence map›Paper›PMID 34601590›Full record

ReviewJournal of industrial microbiology & biotechnology2021

Monoterpenoid biosynthesis by engineered microbes.

Yurou Liu, Xiaoqiang Ma, Hong Liang, Gregory Stephanopoulos, Kang Zhou

Abstract readReview
In one paragraph

Review in Journal of industrial microbiology & biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Modularly engineeringFrontiers in bioengineering and biotechnology · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yurou LiuDepartment of Chemical and Biomolecular Engineering, National University of Singapore, Singapore 117585, Singapore.
Xiaoqiang MaDepartment of Chemical and Biomolecular Engineering, National University of Singapore, Singapore 117585, Singapore.
Hong LiangDepartment of Chemical and Biomolecular Engineering, National University of Singapore, Singapore 117585, Singapore.
Gregory StephanopoulosDisruptive & Sustainable Technologies for Agricultural Precision, Singapore-MIT Alliance for Research and Technology, Singapore 138602, Singapore.
Kang ZhouDepartment of Chemical and Biomolecular Engineering, National University of Singapore, Singapore 117585, Singapore.ORCID 0000-0003-0606-7030

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoterpenoids are C10 isoprenoids and constitute a large family of natural products. They have been used as ingredients in food, cosmetics, and therapeutic products. Many monoterpenoids such as linalool, geraniol, limonene, and pinene are volatile and can be found in plant essential oils. Conventionally, these bioactive compounds are obtained from plant extracts by using organic solvents or by distillation method, which are costly and laborious if high-purity product is desired. In recent years, microbial biosynthesis has emerged as alternative source of monoterpenoids with great promise for meeting the increasing global demand for these compounds. However, current methods of production are not yet at levels required for commercialization. Production efficiency of monoterpenoids in microbial hosts is often restricted by high volatility of the monoterpenoids, a lack of enzymatic activity and selectivity, and/or product cytotoxicity to the microbial hosts. In this review, we summarize advances in microbial production of monoterpenoids over the past 3 years with particular focus on the key metabolic engineering strategies for different monoterpenoid products. We also provide our perspective on the promise of future endeavors to improve monoterpenoid productivity.

Indexed as

Metabolic EngineeringTerpenesLimoneneMonoterpenesLimoneneMonoterpenesTerpenesBiotransformationEscherichia coliMetabolic engineeringMicrobial productionMonoterpenoidsSaccharomyces cerevisiae

Identifiers

PMID34601590
PMCPMC8788732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.